🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Solution for injection in pre-filled syringe without Ustekinumab 90, Solution for injection without Ustekinumab 45, STELARA 45 mg solution for injection, STELARA 90 mg solution for injection in pre-filled syringe, JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  2. Sonelokimab

    MoonLake Immunotherapeutics

    Hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  3. Sonelokimab

    MoonLake Immunotherapeutics

    Arthritis, Psoriatic

    phase 3 small molecule active

    4 trials

  4. Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis (PsA)

    phase 3 small molecule active

    1 trial

  5. Sonelokimab

    MoonLake Immunotherapeutics

    Hidradenitis Suppurativa

    phase 3 small molecule active

    4 trials

  6. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  7. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  8. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (pfs) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  9. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial

  10. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  11. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  12. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial

  13. Sotagliflozin (SAR439954)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials

  14. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  15. Spesolimab - solution for infusion

    Boehringer Ingelheim

    Netherton Syndrome

    phase 3 small molecule terminated

    1 trial

  16. Spesolimab i.v.

    Boehringer Ingelheim

    Hidradenitis Suppurativa

    phase 3 small molecule completed

    1 trial

  17. Spesolimab, Placebo matching to Spesolimab

    Boehringer Ingelheim

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  18. Standard First-Line Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  19. Standard of Care

    AbbVie

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. Subcutaneous Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  21. Sufentanil 30 MCG Sublingual Tablet

    United Therapeutics Europe Ltd

    Traumatic Injury

    phase 3 small molecule completed

    1 trial

  22. Sufentanil Mylan 50 microgrammes/ml solution injectable, MORPHINE HYDROCHLORIDE, CHLORURE DE SODIUM 0,9 % LAVOISIER, solution pour perfusion

    Pari Pharma GmbH

    vaso-occlusive crisis due to sickle cell disease

    phase 3 small molecule active

    1 trial

  23. Sunitinib AqVida 12,5 mg Hartkapseln, QINLOCK 50 mg tablets

    Lacuna Pharma Pty Ltd

    Patients with Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  24. Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources